Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lersivirine versus etravirine with darunavir/ritonavir and optimized NRTI in treatment-experienced HIV-1 infection with NNRTI resistance
2007-004392-19Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lersivirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Pfizer. Primary endpoint: Primary efficacy endpoint. Started Jan 2009; status: terminated.
02
Drugs
lersivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-004392-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004392-19.